A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK.Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years.With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body.

A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK.Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years.With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body.